A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

Lung cancers harboring mesenchymal-to-epithelial transition factor (MET) genetic alterations, such as exon 14 skipping mutations or high-level gene amplification, respond well to MET-selective tyrosine kinase inhibitors (TKI). However, these agents benefit a relatively small group of patients (4%–5%...

Descripción completa

Detalles Bibliográficos
Autores principales: DaSilva, John O., Yang, Katie, Surriga, Oliver, Nittoli, Thomas, Kunz, Arthur, Franklin, Matthew C., Delfino, Frank J., Mao, Shu, Zhao, Feng, Giurleo, Jason T., Kelly, Marcus P., Makonnen, Sosina, Hickey, Carlos, Krueger, Pamela, Foster, Randi, Chen, Zhaoyuan, Retter, Marc W., Slim, Rabih, Young, Tara M., Olson, William C., Thurston, Gavin, Daly, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398133/
https://www.ncbi.nlm.nih.gov/pubmed/34315762
http://dx.doi.org/10.1158/1535-7163.MCT-21-0009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398133/
https://www.ncbi.nlm.nih.gov/pubmed/34315762
http://dx.doi.org/10.1158/1535-7163.MCT-21-0009

Ejemplares similares